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Abstract
Histopathology is considered the gold standard diagnostic method for caninemammary tumors. In 2011, a new histologic classification
for canine mammary tumors was proposed. The present study was a 2-year prospective study that validated the 2011 classification as
an independent prognostic indicator with multivariate analysis in a population of 229 female dogs, identifying subtype-specific median
survival times (MST) and local recurrence/distant metastasis rates. Dogs with benign tumors and carcinoma arising in benign mixed
tumors all had an excellent prognosis.Dogswith complex carcinoma and simple tubular carcinoma also experienced prolonged survival.
Thosewith simple tubulopapillary carcinoma, intraductal papillary carcinoma, and carcinoma andmalignantmyoepithelioma had amore
than 10-fold higher risk of tumor-related death. The prognosis was even worse for adenosquamous carcinoma (MST ¼ 18 months),
comedocarcinoma (MST ¼ 14 months), and solid carcinoma (MST ¼ 8 months). The most unfavorable outcome was for anaplastic
carcinoma (MST ¼ 3 months) and carcinosarcoma (MST ¼ 3 months), which also had the highest metastatic rates (89% and 100%,
respectively). Adenosquamous carcinoma exhibited the highest local recurrence rate (50%). In the same canine population, the tumor
diameter was recognized as a strong predictor of local recurrence/distant metastasis and an independent prognosticator of survival in
the multivariate analysis. Excision margins were predictive only of local recurrence, whereas lymphatic invasion and histologic grade
were predictive of local recurrence/distantmetastasis and survival, althoughonly in univariate analyses. In conclusion, this study validated
the 2011 classification scheme and provided information to be used in the clinical setting and as the basis for future prognostic studies.
Keywords
classification, grade, histology, lymphatic invasion, mammary tumors, margins, prognosis, subtype
Canine mammary tumors (CMTs) are the most common neo-
plasms in female dogs.11 The mainstay of treatment is surgical
removal, which is typically followed by histopathology.19
Although there are new molecular techniques for subtyping
CMTs,3,5,7,18 their use is still limited to a research setting and
implementation is needed before considering their application
in routine diagnostic activity. Therefore, histopathology still
represents the gold standard diagnostic method to classify and
provide prognostic information about dogs with CMTs.
Despite no clear consensus on what information should be
included in the histopathology reports for CMTs, various
authors have suggested including the following information:
tumor subtype, tumor grade, presence/absence of lymphatic
invasion, margins of excision, and tumor diameter.6,11,12,14
In 2011, a new detailed histologic classification of subtypes
of CMTs was published by Goldschmidt and colleagues.4 This
new histologic classification (2011 classification) was based on
the World Health Organization criteria previously published in
1974 and 1999 and included 30 CMT subtypes (23 malignant
and 7 benign). Three subsequent studies investigated the prog-
nostic significance of the 2011 classification.5,12,14 Two studies
retrospectively evaluated a population of 245 and 658 dogs,
respectively, and found a correlation between the 2011 classi-
fication and histologic evidence of lymphatic invasion.5,14 The
third study was prospective, included 65 dogs, and found that
the 2011 classification was able to predict disease-free sur-
vival, overall survival, local recurrence, and distant metastasis.
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However, the small number of animals limited the statistical
evaluation to univariate analysis, and different subtypes of
CMTs were grouped together in 1 category for analysis.12 At
the time of writing, there are no prognostic data available for
each tumor subtype to be used in a clinical setting, and the 2011
classification has not yet been validated as an independent
prognostic indicator in multivariate analysis.
The present study is a prospective 2-year follow-up study in
which the prognostic value of the 2011 classification is inves-
tigated in a population of 229 female dogs. The study follows
the recommended guidelines for the conduct and evaluation of
prognostic studies in veterinary oncology.20 Specific objectives
of the study are as follows.
1. To describe the clinical outcome (tumor-specific over-
all survival, rate of local recurrence, and rate of distant
metastasis) of 14 CMT subtypes classified according to
the 2011 classification.
2. To investigate the prognostic significance of other his-
tologic parameters (grade, lymphatic invasion, infiltra-
tion of the margins of excision, and tumor diameter).
3. To validate the 2011 classification as an independent
prognostic indicator in multivariate analysis.
Materials and Methods
Study Population and Inclusion Criteria
Female dogs were evaluated for inclusion in the study at the time
of submission of a surgically removed mammary mass to the
Diagnostic Service ofVeterinaryAnatomicPathology of theUni-
versity of Padua (Italy). Submission to the above-mentioned
Diagnostic Service required a privacy and informed consent form
that allowed research studies on the submittedmaterial. The sam-
ples were not specifically collected for this study and they were
submitted by veterinary clinical practitioners between January
2008 and December 2012 after surgery as therapeutic interven-
tion. The study, therefore, did not require additional ethical
approval. Dogs included in the study had a single mammary
tumor (either benign or malignant) or multiple mammary tumors
with only 1 of them being malignant, which was the tumor con-
sidered in the study. Dogs with different malignant mammary
tumor subtypes or different benign mammary tumor subtypes
were excluded from the study because of the difficulty in deciding
which tumor would affect the follow-up. To be able to analyze
each tumor subtype, a minimum of 8 cases for that subtype was
the target during recruitment. Recruited cases were not included
in prior studies. Only excisional biopsies were considered (inci-
sional biopsies were excluded from the study). All recruited dogs
had surgery as the only treatment modality and were free of
metastasis on preoperative thoracic radiographs.
Histopathology
Samples of surgically resected mammary neoplasms and corre-
sponding lymph nodes (when available) were fixed in 10% buf-
fered formalin. The tumor diameter (largest tumor diameter) was
measured postfixation at the time of trimming. Cross-sections of
the tumors (3 to 6 sections, depending on the size of the tumor)
were taken and routinely processed for histopathology. The
histologic evaluation was performed jointly by 2 of the authors
(R.R. and V.Z.) or in some cases by 3 of the authors (R.R., V.Z.,
and M.H.G.). At the time of the histologic examination, these
authors were blind to the clinical follow-up. Neoplasms were
histologically classified into subtypes following the 2011 classi-
fication.4 According to this classification, some tumor subtypes
are considered unambiguously malignant by their morphologic
features (eg, solid carcinoma, comedocarcinoma, anaplastic
carcinoma, adenosquamous carcinoma, and carcinosarcoma),
whereas for other subtypes, benign and malignant forms are
described (eg, complex adenoma vs complex carcinoma, simple
adenoma vs simple tubular or tubulopapillary carcinoma, benign
mixed tumor vs carcinoma arising in benignmixed tumor), and in
these cases, the diagnosis of malignancy was based on the
presence of at least 1 of the following features: pluristratification
of the epithelial cells (more than 3 layers), necrosis (presence of at
least 2 randomly distributed foci), marked nuclear pleomorphism
(assessment in the fields with highest degree of anisokaryosis), or
more than 3mitoses in 10 high-power (400) fields (assessment in
the fields with the highest mitotic activity; diameter of the field of
view ¼ 0.55 mm). Identification of neoplastic malignant myoe-
pithelium was performed according to previous studies.13,14 Neo-
plasms were graded using the Pen˜a system,12 although focusing
exclusively on the neoplastic epithelial component as previously
done.13,14 The status of the resected margins (free/not free of
tumor) was also assessed, evaluating at least 3 cross-sections of
the tumor. Lymphatic invasion, defined as infiltration of regional
lymph nodes (when available) and/or lymphatic vessels at the
periphery of the neoplasms, was also determined.
Follow-up
During the follow-up period, dogs received a complete physical
examination and underwent imaging procedures (thoracic
radiographs and abdominal ultrasound) every 3 to 4 months for
a minimum of 2 years as part of the clinical monitoring per-
formed by the veterinary clinical practitioners. Information
recorded included the development of local recurrence, distant
metastases, and tumor-related death. Local recurrence was
defined as the development of a subsequent tumor in the same
location and with the same histologic features as the original
tumor. Metastatic disease was diagnosed using imaging proce-
dures, supported by aspiration cytology when possible and
ethically acceptable. Tumor-related death was clinically
defined as spontaneous death or euthanasia due to tumor-
related issues (local progression or systemic deterioration in
animals with metastatic disease). It is unfortunate that owners
did not give permission for necropsy examination.
Statistical Analyses
Data collected for each dog included age, breed, neuter
status, tumor subtype, grade, lymphatic invasion, margins,
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and tumor diameter. Outcome measures were tumor-specific
overall survival, development of local recurrence, and dis-
tant metastases. Animals that died for reasons unrelated to
their tumors or that were still alive at the end of the follow-
up period were censored because the event tumor-related
death had not occurred.
Associations between tumor-specific overall survival, local
recurrence, and distant metastases, measured as a binary out-
come and age (quartiles), breed, neuter status, tumor diameter
(< 1 cm, between 1 and 2 cm, between 2 and 5 cm, and > 5 cm),
tumor subtype, grade, margins of excision, and lymphatic inva-
sion, were examined using Pearson chi-square test. Kaplan–
Meier survival plots and corresponding nonparametric log-
rank tests and univariate Cox’s proportional hazard regression
analysis (95% confidence interval) were examined for the para-
meters significant in the Pearson chi-square test (tumor sub-
type, grade, margins of excision, lymphatic invasion, tumor
subtype). Multivariate Cox’s proportional hazard regression
analysis was conducted including factors significant in the uni-
variate analysis using a forward stepwise procedure. The sta-
tistical significance was set at 5%. Commercial software was
used for the statistical analysis (IBM SPSS Statistics 21; IBM
Corporation, Chicago, IL, USA).
Results
Characteristics of the Study Population
The individual-animal data are available in Supplemental
Table 1.
Two hundred twenty-nine female dogs were included in
the study. At the time of diagnosis, most of them (63%,
145/229) were intact. Twenty-two breeds were represented
in the study, and among these, German Shepherd and York-
shire Terrier were the most common (13% and 11%, respec-
tively). The ages ranged from 3 to 18 years (median ¼ 10.1
years). The median follow-up for censored dogs was 21
months, ranging from 2 to 39 months, whereas for cases that
died of causes related to the mammary tumor, the median
follow-up was 7 months with a range from 0 to 20 months.
During the follow-up period, 33% (75/229) developed distant
metastases, 13% (31/229) had local recurrence, and 26% (63/
229) died from tumor-related causes. With Pearson chi-square
tests, neuter status, age, and breed were found not to be asso-
ciated with tumor-specific overall survival, local recurrence,
or distant metastases.
Prognostic Significance of the Tumor Subtypes
(2011 Classification)
Of the 229 tumors included in the study, 169 (74%) were
malignant and 60 (26%) were benign. The 14 tumor subtypes
included in the study and the number of cases for each category
are described in Table 1. During the follow-up period, no
events (distant metastases, local recurrence, or tumor-related
death) were registered for dogs with benign tumors (complex
adenoma, benign mixed tumor, simple adenoma) and dogs with
carcinoma arising in benign mixed tumor. Therefore, these 4
tumor subtypes were excluded from the statistical analysis. The
statistical analysis included the other 10 tumor subtypes.
A significant association (log rank; P < .001) was found
between the subtypes of the 2011 classification and the
tumor-specific overall survival. Differences in overall survival
are shown by the Kaplan–Meier curves (Fig. 1). Median sur-
vival time (MST), mean survival time (mST), 1-year and
2-year survival rates, and hazard ratio (HR) for tumor-related
death (univariable Cox regression, reference category: complex
carcinoma) for each subtype are provided in Table 2. Briefly,
anaplastic carcinoma and carcinosarcoma were the most
aggressive tumor subtypes, both having a MST of 3 months
and a mST of 4.2 months. Animals diagnosed with these 2
tumors died within 1 year and had a risk of death more than
150 times higher than dogs with a complex carcinoma. A
slower disease progression was recognized for adenosquamous
carcinoma (MST ¼ 18 months; mST ¼ 12.6 months), come-
docarcinoma (MST ¼ 14 months; mST ¼ 18 months), and
solid carcinoma (MST ¼ 8 months; mST ¼ 15.6 months),
although the risk of dying from tumor-related causes was still
high (25 times more than complex carcinoma). Dogs with sim-
ple tubulopapillary carcinoma, intraductal papillary carcinoma,
and carcinoma and malignant myoepithelioma were more likely
to die than dogs with complex carcinoma (HR ¼ 10.4–13). For
these 3 subtypes, the MST was not reached during the follow-up
period and the mST was more than 19 months. For the same 3
subtypes the 1-year survival rate varied from 70% to 83% and
the 2-year survival rate varied from 50% to 67%. Dogs with
simple tubular carcinoma and complex carcinoma experi-
enced prolonged overall survival.
The 2011 classification showed an association with the
development of local recurrence (chi-square; P ¼ .012) and
distant metastases (chi-square; P < .001). Recurrence and meta-
static rates for each tumor subtype are included in Table 3. In
parallel with the results of the survival analysis, the highest
Table 1. Number of Cases for Each Canine Mammary Tumor
Subtype Included in the Study.
Subtype No. of Cases
Complex adenoma 20
Benign mixed tumor 20
Simple adenoma 20
Complex carcinoma 23
Simple tubular carcinoma 15
Simple tubulopapillary carcinoma 12
Intraductal papillary carcinoma 12
Carcinoma and malignant myoepithelioma 20
Adenosquamous carcinoma 10
Comedocarcinoma 17
Solid carcinoma 20
Anaplastic carcinoma 18
Carcinosarcoma 8
Carcinoma arising in benign mixed tumor 14
Total 229
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metastatic rates were registered for carcinosarcoma (100%) and
anaplastic carcinoma (89%). Distant metastases were also com-
mon in dogs with comedocarcinoma (82%), solid carcinoma
(65%), and adenosquamous carcinoma (60%). The adenosqua-
mous carcinoma was also the tumor that most commonly
recurred (50%), even more than anaplastic carcinoma (44%)
and carcinosarcoma (37%).
Prognostic Significance of Histologic Grade, Lymphatic
Invasion, Margins, and Tumor Diameter
The 169 malignant tumors were graded as follows: 86 (51%)
grade I, 23 (14%) grade II, and 60 (35%) grade III. The distri-
bution of carcinoma subtypes among the grades of malignancy
is described in Table 4. Carcinomas arising in benign mixed
tumor, complex carcinomas, simple tubular carcinomas, simple
tubulopapillary carcinomas, intraductal papillary carcinomas,
carcinoma and malignant myoepitheliomas, and carcinosarco-
mas were mostly classified as grade I, whereas adenosquamous
carcinomas, comedocarcinomas, solid carcinomas, and ana-
plastic carcinomas were usually grade III. The histologic grade
was significantly associated with tumor-specific overall sur-
vival (log rank; P < .001), as shown by the Kaplan–Meier
curves (Fig. 2). Grade III tumors had a MST of 6 months, a
mST of 7.8 months, a 1-year survival rate of 27%, a 2-year
survival rate of 0%, and a 7.1 times higher risk of death (uni-
variate Cox regression; P < .001) compared with grade I. It is
interesting that grade I and grade II tumors behaved similarly,
both categories being associated with a prolonged tumor-
specific overall survival (MST not reached for both grade I and
grade II, mST of 30.3 months for grade I and 33.4 months for
grade II, 1-year survival rate of 81% for grade I and 96%
for grade II, 2-year survival rate of 69% for grade I and 78%
for grade II) (Table 5). The histologic grade was also associated
with local recurrence (chi-square; P ¼ .015) and distant
metastases (chi-square; P < .001), with grade III tumors being
more aggressive (recurrence rate¼ 32%, metastatic rate¼ 87%)
than grade I (recurrence rate¼ 12%, metastatic rate¼ 19%) and
grade II (recurrence rate ¼ 9%, metastatic rate ¼ 30%)
tumors (Table 5).
Table 2. Median and Mean Survival Times (Months), Survival Rates, and Results of the Univariate Cox Regression for Each Subtype of Canine
Mammary Tumor.a
Subtype MST/mST
Survival Rate Univariate Cox Regression
1 Year 2 Year HR P Value
Complex carcinoma nr/36 100% (23/23) 96% (22/23) Reference
Simple tubular carcinoma nr/29.1 93% (14/15) 73% (11/15) 5.6 NS
Simple tubulopapillary carcinoma nr/24.9 75% (9/12) 67% (8/12) 10.4 .037
Intraductal papillary carcinoma nr/19.8 83% (10/12) 50% (6/12) 12.3 .022
Carcinoma and malignant myoepithelioma nr/26.8 70% (14/20) 55% (11/20) 13 .016
Adenosquamous carcinoma 18/12.6 60% (6/10) 0% (0/10) 25.6 .003
Comedocarcinoma 14/18 71% (12/17) 29% (5/17) 25.6 .002
Solid carcinoma 8/15.6 45% (9/20) 25% (5/20) 33.7 .001
Anaplastic carcinoma 3/4.2 0% (0/18) 0% (0/18) 153.4 < .001
Carcinosarcoma 3/4.2 0% (0/8) 0% (0/8) 160.9 < .001
Abbreviations: HR, hazard ratio; mST, mean survival time; MST, median survival time; nr, not reached; NS, nonsignificant.
aP < .05.
Figures 1–3. Kaplan-Meier curves for tumor subtypes (Fig. 1), grades
of malignancy (Fig. 2), and lymphatic invasion (Fig. 3). In each curve the
Y-axis represents the survival probability. Note the difference in
tumor-specific overall survival between dogs with different subtypes
of mammary carcinoma (Fig. 1). There is shorter survival of dogs with
Grade III Tumors and lymphatic invasion (Figs. 2 and 3).
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Lymphatic invasion, defined as infiltration of peritumoral
lymphatic vessels (assessed in all dogs) and/or infiltration of
regional lymph node (available for 92 dogs), was found in 31%
(52/169) of the malignant tumor cases. Significant differences
in tumor-specific survival (log rank; P < .001) (Fig. 3), risk of
death (HR ¼ 8.6, univariate Cox regression; P < .001), local
recurrence (chi-square; P ¼ .019), and distant metastases (chi-
square; P < .001) were identified between dogs with and with-
out lymphatic invasion. As expected, dogs with lymphatic
invasion had a shorter tumor-specific overall survival (MST
¼ 5 months, mST ¼ 7.1 months, 1-year survival rate ¼ 19%,
2-year survival rate ¼ 0%) compared with dogs without lym-
phatic invasion (MST not reached, mST ¼ 30.2 months, 1-year
survival rate ¼ 84%, 2-year survival rate ¼ 69%) and more
frequently developed distant metastases (88% vs 25%) and
local recurrence (31% vs 13%) (Table 5).
Neoplastic infiltration at the excision margins was detected
in 25% (42/169) of the dogs with malignant tumors. Neoplastic
infiltration of margins of excision was significant for local
recurrence (chi-square; P ¼ .003) but did not affect the
tumor-specific overall survival or distant metastases (Table 5).
The tumor diameter, which ranged from 0.2 to 9 cm (median
¼ 3.5 cm), was significantly associated with tumor-specific
overall survival (chi-square; P < .001), local recurrence (chi-
square; P < .001), and distant metastasis (chi-square; P < .001).
Multivariate Cox Regression Survival Analysis
The multivariate Cox regression model included the tumor sub-
type, grade, lymphatic invasion, and tumor diameter (< 1 cm,
between 1 and 2 cm, between 2 and 5 cm, and > 5 cm). The
model was able to explain significantly the variability seen in the
population (P < .001). The only 2 significant independent para-
meters were the tumor subtype (P ¼ .013) and tumor diameter
(P ¼ .025), whereas grade (P ¼ .098) and lymphatic invasion
(P ¼ .283) lost their prognostic value (Table 6).
Discussion
This 2-year prospective follow-up study demonstrated that the
2011 classification is a prognostic indicator for tumor-specific
Table 3. Rates of Local Recurrence and Distant Metastasis for Each
Tumor Subtype (169 Malignant Tumors).
Subtype
Local
Recurrence Rate
Distant
Metastasis Rate
Complex carcinoma 13% (3/23) 4% (1/23)
Simple tubular carcinoma 13% (2/15) 20% (3/15)
Simple tubulopapillary
carcinoma
0% (0/12) 33% (4/12)
Intraductal papillary carcinoma 8% (1/12) 16% (2/12)
Carcinoma and malignant
myoepithelioma
20% (4/20) 40% (8/20)
Adenosquamous carcinoma 50% (5/10) 60% (6/10)
Comedocarcinoma 6% (1/17) 82% (14/17)
Solid carcinoma 20% (4/20) 65% (13/20)
Anaplastic carcinoma 44% (8/18) 88% (16/18)
Carcinosarcoma 37% (3/8) 100% (8/8)
Carcinoma arising in benign
mixed tumor
0% (0/14) 0% (0/14)
Table 4. Distribution of Carcinoma Subtypes (169 Tumors) Among
the Grades of Malignancy.
Subtype Grade I Grade II Grade III
Complex carcinoma 87% (20/23) 13% (3/23) 0% (0/23)
Simple tubular carcinoma 87% (13/15) 13% (2/15) 0% (0/15)
Simple tubulopapillary
carcinoma
58% (7/12) 25% (3/12) 17% (2/12)
Intraductal papillary
carcinoma
58% (7/12) 33% (4/12) 8% (1/12)
Carcinoma and malignant
myoepithelioma
100% (20/20) 0% (0/20) 0% (0/20)
Adenosquamous
carcinoma
10% (1/10) 20% (2/10) 70% (7/10)
Comedocarcinoma 0% (0/17) 11% (2/17) 88% (15/17)
Solid carcinoma 0% (0/20) 30% (6/20) 70% (14/20)
Anaplastic carcinoma 0% (0/18) 0% (0/18) 100% (18/18)
Carcinosarcoma 62% (5/8) 0% (0/8) 37% (3/8)
Carcinoma arising in
benign mixed tumor
93% (13/14) 7% (1/14) 0% (0/14)
Table 5. Survival Rates, Rates of Local Recurrence, and Rates of Distant Metastasis of the 169 Malignant Tumors According to Grade of
Malignancy, Lymphatic Invasion, and Excision Margins.a
Histologic Features
Survival Rate
Local Recurrence Rate Distant Metastasis Rate1 Year 2 Years
Grade I 81% (70/86) 69% (59/86) 12% (10/86) 19% (16/86)
II 96% (22/23) 78% (18/23) 9% (2/23) 30% (7/23)
III 27% (16/60) 0% (0/60) 32% (19/60) 87% (52/60)
Lymphatic invasion Present 19% (10/52) 0% (0/52) 31% (16/52) 88% (46/52)
Absent 84% (98/117) 69% (81/117) 13% (15/117) 25% (29/117)
Margins Not free 43% (18/42) 14% (6/42) 29% (12/42) 52% (22/42)
Free 48% (61/127) 24% (30/127) 15% (19/127) 42% (53/127)
aFree or not free means that neoplastic cells were absent or present, respectively, at the excisional margin.
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overall survival, local recurrence, and distant metastases in
dogs affected by mammary tumors, supporting its application
in routine diagnostic pathology. The main strength of the study
is that it has been specifically designed to have an adequate
number of cases for each tumor subtype to be able to analyze
them separately and identify subtype-specific clinical out-
comes. With this goal in mind, dogs with more than 1 malig-
nant mammary tumor subtype and dogs that received adjuvant
treatments (eg, chemotherapy) were not included in the study to
prevent biases.
The independent prognostic significance retained by the
2011 classification in the multivariate analysis strengthens
the biologic implications of the discovered association with the
tumor-specific overall survival. The 14 subtypes analyzed in
the study are the most common mammary tumor subtypes in
dogs,4,5,12 and the results obtained in terms of tumor-specific
overall survival, recurrence, and distant metastases are consid-
ered potentially relevant information for clinicians and oncol-
ogists for prognostication and clinical decision making.
As expected, the 3 benign subtypes included in the study
(complex adenoma, benign mixed tumor, and simple adenoma)
did not recur or metastasize and were not associated with the
animal’s death, suggesting that the histologic criteria of malig-
nancy used (more than 3 layers of epithelial stratification,
randomly distributed areas of necrosis, marked nuclear pleo-
morphism assessed in the areas of highest degree of anisokar-
yosis, and more than 3 mitoses in 10 high-power fields assessed
in the fields with the highest mitotic activity) did not lead to
underestimation of malignancy. It is interesting that carcinoma
arising in benign mixed tumor, which was predominantly clas-
sified as grade I, had a biologic behavior similar to the benign
subtypes. This result could support the hypothesis that this is a
tumor in the early phases of malignant transformation,4,14 or it
could be argued that our histologic criteria of malignancy are
too strict and might lead to an overestimation of the malig-
nancy. Further research is warranted to refine the histologic
criteria to differentiate this tumor from its benign counterpart
(benign mixed tumor) and, in general, to understand the clinical
implications of detecting foci of malignancy within an other-
wise benign-looking mammary neoplasm.
Similar to previous studies,1,2 we noted that anaplastic car-
cinomas had a worse prognosis than solid carcinomas, and
solid carcinomas were more aggressive than simple tubulopa-
pillary carcinomas and complex carcinomas. Besides, we dis-
covered that carcinosarcomas had a mortality pattern similar to
anaplastic carcinomas, with dramatically short tumor-specific
overall survival times and high rates of local recurrence and
distant metastases.
The biologic behavior of the adenosquamous carcinoma was
also described for the first time with longer tumor-specific
overall survival than anaplastic carcinoma and carcinosarcoma
but a higher propensity for local recurrence (half of the cases).
This tendency for local relapse might be attributable to the
squamous component of the tumor, which when present in
other anatomic locations is locally invasive (eg, cutaneous and
oral squamous cell carcinoma).19 On the contrary, comedocar-
cinoma was the most commonly metastatic tumor after ana-
plastic carcinoma and carcinosarcoma, which substantiates our
previous findings on a different canine population.14
The prognosis associated with canine intraductal papillary
carcinoma had never been documented, and in this study, it
appeared to be more favorable than that of other subtypes
(eg, anaplastic carcinoma, carcinosarcoma, solid carcinoma,
comedocarcinoma, adenosquamous carcinoma), although more
cases are required to draw a more definitive conclusion on
the behavior of this recently described subtype. It would also
be interesting to compare the prognosis of the intraductal papil-
lary carcinoma with that of the ductal carcinoma (not included
in this study), which is believed to have a similar origin to the
ductal system but displays a different type of growth and cell
morphology (intraductal papillary carcinoma has papillae
formed by columnar cells with moderate cytoplasm and
open-faced nuclei, whereas ductal carcinoma has bilayered
cords formed by cuboidal cells with scant cytoplasm and hyper-
chromatic nuclei).4 These 2 duct-associated tumor subtypes
have been recently described in cats, with preliminary
follow-up data suggesting that they have a less aggressive
behavior compared with other mammary carcinomas.22
Survival analysis revealed a lower risk of tumor-related
death for dogs with complex carcinoma compared with dogs
with carcinoma and malignant myoepithelioma, confirming
previous findings13 and supporting the hypothesis of a protec-
tive role of well-differentiated myoepithelium as it occurs in
complex carcinoma.13–15 In addition, the present study
Table 6. Multivariate Cox Regression Model Including Tumor
Subtype, Grade, Lymphatic Invasion, and Tumor Diameter.
Variable Category
Multivariate Cox
Regression
HR
P
Value
Subtype Complex carcinoma Reference .013
Simple tubular carcinoma 10.9 .045
Simple tubulopapillary carcinoma 10.1 .042
Intraductal papillary carcinoma 16.2 .012
Carcinoma and malignant
myoepithelioma
11.9 .023
Adenosquamous carcinoma 10.7 .041
Comedocarcinoma 9.4 .045
Solid carcinoma 13.1 .027
Anaplastic carcinoma 18.2 .021
Carcinosarcoma 71.1 < .001
Grade I Reference NS
II 0.6 NS
III 2.7 NS
Lymphatic
invasion
Absent Reference NS
Present 1.61 NS
Diameter Less than 1 cm Reference .025
Between 1 and 2 cm 2.9 .038
Between 2 and 5 cm 2.7 .045
More than 5 cm 9.5 .02
Abbreviations: HR, hazard ratio; NS, nonsignificant.
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demonstrated that, despite being associated with a more
guarded prognosis compared with complex carcinoma, the car-
cinoma and malignant myoepithelioma is not a very aggressive
mammary malignancy in dogs, with most animals still alive 2
years after surgery. This is supported by the less aggressive
pathologic features described by Yoshimura and colleagues21
in tumors with a malignant myoepithelium compared with sim-
ple solid carcinomas.
It is rather surprising that there was no difference in the
tumor-specific overall survival of dogs with simple tubular
carcinoma compared with dogs with complex carcinoma. This
contradicts previous results from our group14 and other
research groups1,6,11 and is likely to be a reflection of the high
proportion of grade I (87%) simple tubular carcinomas in this
study compared with previous studies, suggesting that this find-
ing should be interpreted with caution and that grade may be
considered particularly relevant for the prognostication of this
tumor subtype.
Less common mammary tumor subtypes such as lipid-rich
carcinoma, micropapillary invasive carcinoma, and benign
myoepithelioma were not included in this study due to the
inadequate number of cases recruited. A multi-institutional
approach in the future could help in overcoming this limitation,
clarifying the biologic behavior also for these uncommon
tumor entities.
Corroborating previous findings,1,6,12 our study showed that
grade, lymphatic invasion, and tumor diameter were associated
with tumor-specific overall survival, recurrence, and distant
metastases. However, lymphatic invasion and grade lost their
prognostic power in the multivariate survival analysis since
tumor diameter and subtype were able to significantly explain
the variability in tumor-specific overall survival within this
cohort of dogs.
As the size of the metastatic deposits in the lymph node has
been recently demonstrated to have a significant effect on sur-
vival,2 future studies should take into consideration this addi-
tional aspect, which could potentially be an independent
prognostic factor superior to the simple assessment of presence
or absence of lymphatic invasion.
With respect to the tumor grade, our survival rates were
similar to those reported by other authors,6,12 although they
were slightly lower for grade I tumors. This could be due to
intrinsic differences in the study populations and/or variations
in how the grade has been calculated, as a certain degree of
interobserver variability has been repeatedly documented in
recent studies.16,17 We adopted the grading system published
by Pen˜a and colleagues,12 with the only difference being that
we focused our evaluations on the neoplastic epithelial compo-
nent only, as previously done.6,9,13,14 Since we did not consider
for grading purposes other tumor cell populations (myoepithe-
lial and mesenchymal), an underestimation of malignancy in
cases of carcinoma and malignant myoepithelioma and carci-
nosarcoma is possible, which could explain the lower survival
rates of our grade I tumors compared with the study by Pen˜a
et al.12 The reason for our choice is that specific criteria to
estimate the malignancy of myoepithelial cells and
mesenchymal cells in biphasic tumors, substantiated by the
clinical outcome, have not yet been precisely established in the
literature. We believe that further research on this topic is
crucial in order to accurately and reliably prognosticate bipha-
sic mammary tumors in dogs.
As in previous studies, we noted that it is the switch from
grade I to grade III (not the switch from Grade I to Grade II)
that is prognostic for tumor-specific overall survival. Grade II
tumors behave similarly to grade I tumors, with prolonged
overall survival times and low rates of local recurrence and
distant metastasis.9,12 This could open the debate about the
utility of the grade II category in the clinical setting. Further
research in this area may include the improvement of the 3-tier
histologic grading system, as lately performed for feline mam-
mary tumors modifying the range subcategories within the
mitotic count and the assessment of the nuclear morphology.10
An alternative could be the development of a 2-tier histologic
grading system, as recently done for canine cutaneous mast cell
tumors.8
The ability of the neoplastic extension to margins to predict
local recurrence, but not distant metastasis or tumor-specific
overall survival, is intuitive and has been demonstrated for
other canine malignancies,19 but to the best of our knowledge,
this is the first time that this is reported in CMTs.
In conclusion, this study validated in multivariate analysis
the 2011 classification as an independent prognostic indicator
in dogs with mammary tumors, suggesting that this could be
used as the basis for future studies to look at other prognostic
markers and therapeutic interventions. Subtype-specific clin-
ical outcomes were described and these represent potentially
relevant information for clinicians and oncologists for prog-
nostication and clinical decision making. The tumor diameter
was confirmed to be an independent prognostic factor in dogs
with mammary tumors, and the excisional margins were
found to be predictive of local recurrence only, similar to
other canine neoplasms.
Lymphatic invasion and histologic grade were also proven
to be prognostically relevant, although in this study population,
they were not confirmed to be independent prognosticators.
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